About Merit Medical Systems, Inc. - Common Stock (MMSI)
Merit Medical Systems is a global medical device company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and supplies for various clinical applications. The company focuses primarily on products used in the fields of interventional cardiology, radiology, and critical care, offering innovative solutions that enhance patient care and treatment outcomes. Merit's portfolio includes advanced catheter systems, diagnostic and therapeutic products, as well as specialty surgical devices. With a commitment to quality and innovation, Merit Medical aims to meet the evolving needs of healthcare professionals and improve the overall healthcare experience for patients. Read More
Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q1 CY2025, with sales up 9.8% year on year to $355.4 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.8% above analysts’ consensus estimates.
Medical device company Merit Medical Systems (NASDAQ:MMSI)
will be announcing earnings results tomorrow after the bell. Here’s what investors should know.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Merit Medical Systems (NASDAQ:MMSI) and the rest of the medical devices & supplies - cardiology, neurology, vascular stocks fared in Q4.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and its peers.
Merit Medical guides below consensus on FY25 EPS, projects up to $1.49 billion revenue, and faces tariff risks amid ongoing global manufacturing expansion.
Since April 2020, the S&P 500 has delivered a total return of 121%. But one standout stock has doubled the market - over the past five years, Merit Medical Systems has surged 247% to $105.49 per share. Its momentum hasn’t stopped as it’s also gained 10% in the last six months, beating the S&P by 13.3%.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including ICU Medical (NASDAQ:ICUI) and its peers.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Medical device company Merit Medical Systems (NASDAQ:MMSI) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.4% year on year to $355.2 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.93 per share was 12.2% above analysts’ consensus estimates.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSE:AORT) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including ICU Medical (NASDAQ:ICUI) and its peers.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems (NASDAQ:MMSI) and its peers.
